Compare PulteGroup, Inc. (PHM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? PulteGroup, Inc. trades at $126.7 (market cap $23.67B), while State Street SPDR S&P Biotech ETF trades at $151.92. The key difference: PulteGroup, Inc. pays a 0.84% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, PulteGroup, Inc. nearer its low. Which is the better fit depends on your goals.
| PHM | XBI | |
|---|---|---|
Market Cap | $23.67B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $142.56 | $164.28 |
52-Week Low | $110.11 | $85.16 |
Enterprise Value | $23.63B | — |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $124.26, down 1.44% over the past day, with technical indicators showing a bearish trend. The stock exhibits strong profitability with a net income margin of 12.14% and ROE of 16.18%, though recent quarters saw mixed earnings results. Valuation ratios remain attractive with a P/E of 11.91 and P/S of 1.44. Recent news highlights institutional activity and anticipation for Q2 2026 earnings, with the company expanding communities amid housing market challenges.
The outlook for PHM is cautiously optimistic, supported by solid fundamentals and a consensus price target of $146.50 implying 18% upside. Risks include margin pressure from high mortgage rates and competitive discounts. Analyst sentiment is balanced with 45% buy ratings, but investors should monitor earnings execution and housing demand trends for sustained growth.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
